News Center
Shanghai Pharma Investment Cooperation Forum was held at HKSTPC to discuss innovation cooperation

On March 28, the Shanghai Pharma Investment Cooperation Forum was held at Hong Kong Science & Technology Park. The exchange contributed to lay a foundation for future establishment of a closer investment and cooperation relationship between Shanghai Pharma (SPH) and Hong Kong Science & Technology Parks Corporation (HKSTPC).

For SPH, a leading Chinese pharmaceutical group with dual listings in Shanghai and Hong Kong’s stock exchanges, Hong Kong presents several advantages: a favorable business environment, many different innovative platforms and large human resources. This cooperation would further boost SPH’s international development. HKSTP’s strength in innovative R&D is brought by renowned universities and scientific research institutions. Shanghai Pharma’s strengths are in manufacturing and marketing of pharmaceuticals. The combination of these strengths will promote and foster unicorns in the bio-pharmaceutical industry.

SIIC Party Secretary and Chairman Mr. Shen Xiaochu, SIIC President and Shanghai Pharma Chairman Mr. Zhou Jun, Shanghai Pharma Executive Director and President Mr. Cho Man, held discussions on promoting innovation and cooperation with HKSTPC Chairwoman Ms. Fanny Law and her team. The two sides further exchanged constructive views on subsequent coordination.

Mr. Cho Man expressed his wish to combine SPH’s resources with HKSTP’s innovative R&D to promptly bring to market outstanding products that will benefit public health.

HKSTPC is committed to linking tech enterprises to potential investors; enhancing closer collaboration among enterprises, local universities and research institutions; promoting the development of the new, vibrant and innovative sci-tech ecosystem in Hong Kong. Ms. Fanny Law noted that the forum was the first step towards substantive cooperation between both sides. Further coordination is anticipated, and HKSTPC will provide continuous support to R&D enterprises at the park.

The forum was chaired by Shanghai Pharma VP Mr. Liu Yanjun. Shanghai Pharma’s VP and Board Secretary Mr. Liu Dawei, VP Mr. Zhang Yaohua, Deputy Director of R&D Management Center Ms. Ke Ying, and Executive Director of SPH Hong Kong Investment Mr. Frederick Mocatta respectively introduced the overall situation of the company, its manufacturing performance, research and development projects and investment strategy.

Following the group presentations, two SPH teams (including management and relevant staff) held initial talks and negotiations with eight (8) promising start-ups.

Shanghai and Hong Kong have a history of close and successful cooperation in numerous industries. Shanghai Industrial Investment (Holdings) Co., Ltd. (SIIC), is a powerful state-owned company based in Shanghai. SIIC has heavily invested in overseas businesses ventures. It is involved in five major areas - pharmaceuticals, infrastructure, real estate, consumer goods and financial investment. SIIC is currently exploring business opportunities in new industries. The company has had a presence in Hong Kong for over 30 years.

The bio-pharmaceutical industry is thriving in Hong Kong. SPH wishes to collaborate with local research institutions to provide innovative R&D. The goal of this collaboration is to rejuvenate China’s pharma industry, promote the “Made in China” brand worldwide and make a meaningful contribution to public health.


The subject of concern
Produced By 大汉网络 大汉版通发布系统